Mark Kochenderfer, MD
Hematology & Oncology · Roanoke, VANPI 1396720454
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,450 of the $12,961 with a category attached, or 96.1%. Merck accounts for 96.1% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2021 at $12,462 and has fallen 98.6% since, to $172 in 2025. Among hematology & oncology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 26 payments — averaging $498.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$12K
- Tactile Systems Technology Inc$90
- Puma Biotechnology, Inc.$65
- Daiichi Sankyo Inc.$61
- Genentech, Inc.$53
- Pfizer$35
- plus $206 from 10 others
Across 1,716 payments — averaging $4991.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$5.5M
- Pfizer$1M
- E.r. Squibb & Sons, L.L.C.$713K
- Gilead$247K
- Ipsen Bioscience Inc.$243K
- Taiho Oncology, Inc.$219K
- plus $669K from 11 others
What the payments were for
- Consulting fees$12,45096%
- Food & beverage$4253%
- Education$871%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 1 | $12,450 |
| Tactile Systems Technology Inc | 3 | $90 |
| Puma Biotechnology, Inc. | 3 | $65 |
| Daiichi Sankyo Inc. | 3 | $61 |
| Genentech, Inc. | 1 | $53 |
| Pfizer | 4 | $35 |
| Novartis | 1 | $33 |
| Bristol Myers Squibb | 2 | $30 |
| Beone Medicines USA, Inc. | 1 | $27 |
| Array Biopharma Inc | 1 | $20 |
| Rigel Pharmaceuticals, Inc. | 1 | $20 |
| AbbVie | 1 | $20 |
| Beigene USA, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $14 |
| Gilead | 1 | $12 |
| Teleflex LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WELIREG$12,450
How this compares
$12,961 in reported general payments places this provider in the 90th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 93 | $1,314,714 |
| IbrancePalbociclib | 40 | $641,272 |
| TasignaNilotinib Hcl | 27 | $539,278 |
| XtandiEnzalutamide | 28 | $375,676 |
| OrserduElacestrant Hcl | 16 | $360,628 |
| RevlimidLenalidomide | 21 | $312,917 |
| ImbruvicaIbrutinib | 19 | $280,783 |
| CalquenceAcalabrutinib Maleate | 17 | $244,027 |
| Imatinib Mesylate | 37 | $39,038 |
| Abiraterone Acetate | 19 | $28,198 |
| EliquisApixaban | 39 | $24,878 |
| Letrozole | 253 | $4,275 |
| Exemestane | 13 | $3,582 |
| Anastrozole | 83 | $1,381 |
| Tamoxifen Citrate | 59 | $1,166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $18 | $1,314,71493 claims |
| PfizerIbrance, Eliquis | $35 | $666,14979 claims |
| NovartisTasigna | $33 | $539,27827 claims |
| Bristol Myers SquibbRevlimid | $30 | $312,91721 claims |
| Lilly USA, LLCOlanzapine | $14 | $54962 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 293 hematology & oncology providers in Virginia.
Other hematology & oncology in Roanoke
- Ruby KochharHampton$236K
- Victor YazbeckRichmond$190K
- David ChangNewport News$141K
- William ErshlerFairfax$139K
- Yue ZhangVirginia Beach$105K
- Jerome GoldschmidtChristiansburg$105K
- Attique SamdaniRichmond$104K
- Gary SimmonsNorfolk$82K
- Mark FlemingHampton$71K
- Sekwon JangFairfax$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.